marked.bio

IL-2-redirecting antibody · antibody

AU-007

1 active trials across 2 of our biomarkers, targeting IL-2. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 1 1 Phase 1/2
BRAF V600E 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of AU-007.

  1. Aulos Bioscience 1

Trials

1 of 1 trials shown

  1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

    Recruiting Phase 1/2 Aulos Bioscience Started 2022Primary completion 2027-02 NCT05267626

    AU-007aldesleukinavelumabnivolumab

    BRAF mutation: patients who refused BRAF+MEK inhibitor

    BRAF V600EALK fusionAdvanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer